FDA approves IND Application for Ph 2/3 Study of JS207 for the Neoadjuvant Treatment of NSCLC Patients October 21, 2025
Kazia Therapeutics Announces Collaboration and In-Licensing Agreement with QIMR Berghofer for a first-in-class PD-L1 degrader program October 16, 2025
Ph 2 study of BND-22 (SAR444881) + anti-PD-1 therapy in IO-refractory NSCLC or IO-naive MSS-CRC or ovarian cancer to be initiated October 16, 2025
First Patient Enrolled in TRUST-IV Ph 3 Study of IBTROZI™ (taletrectinib) for the Adjuvant Treatment of Early-Stage ROS1+ve NSCLC October 8, 2025
ASTRO 2025: Final Results from Pivotal Ph 3 METIS Trial of TTFields Therapy for Brain Mets from NSCLC presented October 8, 2025
THIO-101 Ph 2 trial to enroll patients in the U.S. as part of the expansion of the study in 3L treatment for advanced NSCLC September 30, 2025
NDA for A400/EP0031 Accepted for Review by the NMPA for the Treatment of RET-fusion positive NSCLC September 30, 2025
Enrollment completed in Ph 2 Combi-TED Trial of Tedopi® in Combination with Nivolumab or Docetaxel in Patients with NSCLC September 16, 2025
Asia cohort of Ph 3 MARIPOSA study shows RYBREVANT® (amivantamab-vmjw) + LAZCLUZE® (lazertinib) achieved statistically significant OS improvement vs osimertinib in EGFRm NSCLC September 16, 2025
WCLC 2025: Final Analysis of Firmonertinib Monotherapy Data from Ph 1b Study in EGFR PACC Mutant NSCLC presented September 16, 2025
WCLC 2025: Libtayo + chemo demonstrates a more than double 5yr OS rate of 19.4% vs 8.8% with chemo alone in NSCLC September 16, 2025
WCLC 2025: Cadonilimab – Pulocimab Combo Shows Promising Results in IO-Resistant NSCLC September 16, 2025
WCLC 2025: Updated efficacy and safety data presented from Ph 2b REZILIENT1 trial of zipalertinib in EGFRm, amivantamab-ref NSCLC patients September 16, 2025
Positive efficacy data announced from Ph 2 trial of THIO-101 & cemiplimab (Libtayo®) in NSCLC patients who had failed two or more SoC therapy regimens September 16, 2025
Tagrisso + chemo demonstrated a median OS of nearly four years in global Ph 3 FLAURA2 trial in EGFR-mutated advanced NSCLC September 10, 2025
FDA grants HERNEXEOS® Breakthrough Therapy Designation in HER2 (ERBB2)m advanced 1L NSCLC September 10, 2025
WCLC 2025: New HERNEXEOS® data demonstrated promising intracranial responses in patients with advanced HER2m NSCLC with brain mets September 9, 2025
WCLC 2025: RYBREVANT® (amivantamab-vmjw) + LAZCLUZE® (lazertinib) prevents acquired resistance versus osimertinib in 1L EGFRm NSCLC September 9, 2025
WCLC 2025: Longer-Term Follow-Up of Patients Showed Improving, Favorable Trend in OS in Ph 3 HARMONi Clinical Trial for Ivonescimab + Chemo in 2L+ EGFRm NSCLC September 9, 2025
WCLC 2025: New Data from Pivotal Clinical Studies of IBTROZI™ (taletrectinib) in Advanced ROS1-Positive NSCLC Announced September 9, 2025
HERNEXEOS® approved in China for previously treated patients with HER2-mutant advanced NSCLC September 3, 2025
FDA granted Breakthrough Therapy Designation and Orphan Drug Designation for D3S-001 for Patients with KRAS G12C-Mutated Cancers September 3, 2025
First Patient Dosed in Expansion Cohorts of Ph 1/2 SOLARA Trial of BH-30643 in Advanced EGFRm NSCLC September 3, 2025
